Given the success of incretin-based drugs in treating both diabetes and obesity, and their potential for treating NAFLD, further dissection of the regulation of hepatic metabolic pathways by DPP4 is warranted (27–33). Here, DPP4 is linked to metabolic dysfunction-associated steatotic liver disease.